AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8452172 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (AMX/CP), 400 mg/125 mg three times a day for 4-21 days
Number of subjects: 113
Study 3762243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service plan
Number of subjects: 0
Study 3762243 — intervention group
Group type: COMPARATOR
Intervention: HMO plan
Number of subjects: 0
Study 3762243 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO and fee-for-service plans
Number of subjects: 0
Study 29108664 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days sodium nitrate ingestion (∼8 mmol/day)
Number of subjects: 20
Study 29108664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 20
Study 26545726 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 22
Study 26545726 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study 24362589 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186
Study 24362589 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study 22733310 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback of movement trajectory error
Number of subjects: 20
Study 22733310 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback of movement trajectory error
Number of subjects: 20
Study 22733310 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback of error with trapezoid reference trajectory
Number of subjects: 20
Study 22733310 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback of error with trapezoid reference trajectory
Number of subjects: 20
Study 20513863 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine and indoleamine depletion
Number of subjects: 0
Study 20513863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18191734 — intervention group
Group type: EXPERIMENTAL
Intervention: RGEA
Number of subjects: 172
Study 18191734 — intervention group
Group type: COMPARATOR
Intervention: SVG
Number of subjects: 172
Study 16416150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal normobaric hypoxia (8 hours per day for 3 consecutive days)
Number of subjects: 11
Study 16416150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal normobaric hypoxia
Number of subjects: 11
Study 16416150 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxic air for 8 hours per day for 3 consecutive days)
Number of subjects: 11
Study 12827347 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 39
Study 12827347 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 39
Study 12827347 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 39
Study 10832515 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based process tracing method using spoken answers and think aloud instructions.
Number of subjects: 0
Study 10832515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Information Search (AIS) technique (as a basis for the method).
Number of subjects: 0
Study 9086688 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects regression models
Number of subjects: 0
Study 9086688 — intervention group
Group type: COMPARATOR
Intervention: Traditional ANOVA models
Number of subjects: 0
Study 8227449 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF + SnF mouthwash (0.025% fluoride)
Number of subjects: 79
Study 8227449 — intervention group
Group type: COMPARATOR
Intervention: NaF mouthwash (0.05% fluoride)
Number of subjects: 79
Study 8227449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 3762014 — intervention group
Group type: COMPARATOR
Intervention: L-penbutolol (40 mg)
Number of subjects: 0
Study 3762014 — intervention group
Group type: COMPARATOR
Intervention: D-penbutolol (40 mg)
Number of subjects: 0
Study 3762014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31306465 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administered brief HIV risk reduction intervention
Number of subjects: 0
Study 31306465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28184431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib in combination with pemetrexed
Number of subjects: 0
Study 28184431 — intervention group
Group type: COMPARATOR
Intervention: Placebo-pemetrexed
Number of subjects: 0
Study 25657183 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1733
Study 25657183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1733
Study 23904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (SMART™)
Number of subjects: 482
Study 23904191 — intervention group
Group type: COMPARATOR
Intervention: Free combination of inhaled corticosteroid (ICS) + long‐acting β2‐agonist (LABA) and as‐needed short‐acting β2‐agonist (SABA)
Number of subjects: 482
Study 21508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (100 μg/d)
Number of subjects: 932
Study 21508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (4000 μg/wk)
Number of subjects: 932
Study 21508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d)
Number of subjects: 932
Study 21508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (4000 μg/d)
Number of subjects: 932
Study 21508090 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR genotype (TT vs CC)
Number of subjects: 932
Study 19540137 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 5000
Study 19540137 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting (CAS)
Number of subjects: 5000
Study 16282699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (125 mg) + oral calcium (500 mg/day) for 3 months
Number of subjects: 44
Study 16282699 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium (500 mg/day) for 3 months
Number of subjects: 44
Study 15520997 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation
Number of subjects: 117
Study 15520997 — intervention group
Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 117
Study 11287080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivagabine (900 mg, twice a day)
Number of subjects: 20
Study 11287080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9209770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (headache sufferers)
Number of subjects: 53
Study 9209770 — intervention group
Group type: COMPARATOR
Intervention: Group I (non-headache subjects)
Number of subjects: 53
Study 8490077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 8490077 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 8490077 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0
Study 3447933 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13-6438 (10 mg)
Number of subjects: 6
Study 3447933 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13-6438 (20 mg)
Number of subjects: 6
Study 3447933 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13-6438 (30 mg)
Number of subjects: 6
Study 3447933 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13-6438 (all doses)
Number of subjects: 6
Study 30854903 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week physical activity intervention
Number of subjects: 66
Study 30854903 — intervention group
Group type: COMPARATOR
Intervention: Stress-management counseling intervention
Number of subjects: 66
Study 31025658 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography-Guided Fine-Needle Aspiration (EUS-FNA)
Number of subjects: 46
Study 31025658 — intervention group
Group type: COMPARATOR
Intervention: Key-Hole Biopsy (KHB)
Number of subjects: 46
Study 31025658 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA and KHB (combined results)
Number of subjects: 46
Study 31025658 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA and KHB (mitotic activity)
Number of subjects: 46
Study 30226494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track intervention
Number of subjects: 60
Study 30226494 — intervention group
Group type: COMPARATOR
Intervention: Conventional attention
Number of subjects: 60
Study 27665225 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+ stem cell therapy
Number of subjects: 40
Study 27665225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24643340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 522
Study 24643340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 522
Study 24643340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (both types)
Number of subjects: 522
Study 24643340 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet groups
Number of subjects: 522
Study 22610121 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM (Nerve Integrity Monitor Pulse II)
Number of subjects: 880
Study 22610121 — intervention group
Group type: COMPARATOR
Intervention: Neurosign (Neurosign 1040 - 4 Channel EMG)
Number of subjects: 880
Study 20825743 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and Metformin Therapy
Number of subjects: 0
Study 20825743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18556906 — intervention group
Group type: EXPERIMENTAL
Intervention: Specifically matched coloured filters
Number of subjects: 49
Study 18556906 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group with filters in a colour complementary to the individual's optimal colour
Number of subjects: 49
Study 18556906 — intervention group
Group type: COMPARATOR
Intervention: Control group who received no intervention
Number of subjects: 49
Study 16020407 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein 15 g/d
Number of subjects: 117
Study 16020407 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein 25 g/d
Number of subjects: 117
Study 16020407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 16020407 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (both dosages)
Number of subjects: 117
Study 16020407 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117
Study 12501950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic standing (voluntary activation of lower leg muscles in able-bodied)
Number of subjects: 29
Study 12501950 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary standing (FES-induced activation of lower leg muscles in spinal cord-injured)
Number of subjects: 29
Study 12501950 — intervention group
Group type: COMPARATOR
Intervention: Stationary standing
Number of subjects: 29
Study 12501950 — intervention group
Group type: COMPARATOR
Intervention: Dynamic standing
Number of subjects: 29
Study 10360490 — intervention group
Group type: COMPARATOR
Intervention: Non-encrypted transmission
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: 56-bit encryption
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: 128-bit encryption
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: 128-bit encryption with password
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 connection
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dial-up modem connection
Number of subjects: 14
Study 10360490 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy
Number of subjects: 14
Study 8566673 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 250mg plus Amoxicillin 500mg T.I.D for 10 days
Number of subjects: 63
Study 8566673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1785002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 60
Study 1785002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 60
Study 1785002 — intervention group
Group type: COMPARATOR
Intervention: Control (resection only)
Number of subjects: 60
Study 7010651 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation therapy (700 rads X 2)
Number of subjects: 248
Study 7010651 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 248
Study 30727962 — intervention group
Group type: COMPARATOR
Intervention: Experimental Group-8 (EG8)
Number of subjects: 132
Study 30727962 — intervention group
Group type: COMPARATOR
Intervention: Experimental Group-4 (EG4)
Number of subjects: 132
Study 30727962 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 132
Study 30157822 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlider file (PG)
Number of subjects: 60
Study 30157822 — intervention group
Group type: EXPERIMENTAL
Intervention: PathFile (PF)
Number of subjects: 60
Study 30157822 — intervention group
Group type: COMPARATOR
Intervention: K-file (KF)
Number of subjects: 60
Study 25421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Peanuts (CVP)
Number of subjects: 65
Study 25421236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Oleic Peanuts (HOP)
Number of subjects: 65
Study 25421236 — intervention group
Group type: COMPARATOR
Intervention: Control Biscuit (CT)
Number of subjects: 65
Study 24447296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg.kg(‐1)
Number of subjects: 213
Study 24447296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1.5 μg.kg(‐1)
Number of subjects: 213
Study 24447296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 2 μg.kg(‐1)
Number of subjects: 213
Study 22915643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (20 mg/kg/d)
Number of subjects: 193
Study 22915643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 21067805 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily
Number of subjects: 12064
Study 21067805 — intervention group
Group type: COMPARATOR
Intervention: 20 mg simvastatin daily
Number of subjects: 12064
Study 17922743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoscan and Crit‐Line combination
Number of subjects: 14
Study 17922743 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM and Crit‐Line combination
Number of subjects: 14
Study 17922743 — intervention group
Group type: COMPARATOR
Intervention: Crit‐Line
Number of subjects: 14
Study 17922743 — intervention group
Group type: COMPARATOR
Intervention: Hemoscan
Number of subjects: 14
Study 17922743 — intervention group
Group type: COMPARATOR
Intervention: BVM
Number of subjects: 14
Study 17922743 — intervention group
Group type: COMPARATOR
Intervention: DeltaRBV from all devices
Number of subjects: 14
Study 15951873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 12 weeks)
Number of subjects: 32
Study 15951873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 32
Study 12465197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal bath
Number of subjects: 15
Study 12465197 — intervention group
Group type: COMPARATOR
Intervention: Conventional tub bath
Number of subjects: 15
Study 10068580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous interleukin-2 (7.5 million IU twice a day)
Number of subjects: 49
Study 10068580 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous interleukin-2 (1.5 million IU twice a day)
Number of subjects: 49
Study 7478680 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine solution taken at 4-hourly intervals for 7 days under direct nursing supervision
Number of subjects: 26
Study 7478680 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine solution
Number of subjects: 26
Study 2343159 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about losses without follow-up or gains with follow-up
Number of subjects: 116
Study 2343159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 116
Study 7443365 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 40
Study 7443365 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular relaxation
Number of subjects: 40
Study 7443365 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and relaxation
Number of subjects: 40
Study 7443365 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment control
Number of subjects: 40
Study 31170627 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based acute pain management education program (400 min duration, 8 modules, 29 topics)
Number of subjects: 50
Study 31170627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study 28030716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 4644
Study 28030716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4644
Study 26340807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 36
Study 26340807 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 36
Study 23582742 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKIs (gefitinib, erlotinib, afatinib)
Number of subjects: 0
Study 23582742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-associated protein signature (RAPS)
Number of subjects: 0
Study 21317645 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-debriefing
Number of subjects: 50
Study 21317645 — intervention group
Group type: COMPARATOR
Intervention: Instructor debriefing
Number of subjects: 50
Study 19139332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 418
Study 19139332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 418
Study 19139332 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin PDT
Number of subjects: 418
Study 17209188 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (100 mg Fe/d as ferrous gluconate)
Number of subjects: 13
Study 17209188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15182139 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born adolescents
Number of subjects: 766
Study 15182139 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication taking behavior
Number of subjects: 766
Study 15182139 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with both parents
Number of subjects: 766
Study 15182139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Number of subjects: 766
Study 15182139 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking mostly or only English with parents
Number of subjects: 766
Study 15857737 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 224
Study 10348714 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 499
Study 10348714 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin (4,500 anti‐Factor IU Xa)
Number of subjects: 499
Study 8739025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin (35 to 300 mg)
Number of subjects: 0
Study 1764497 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/day), enalapril (5-20 mg/day), and hydrochlorothiazide (12.5-25 mg/day) as necessary.
Number of subjects: 3000
Study 1764497 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 3000
Study 1764497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebos)
Number of subjects: 3000
Study 7123111 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year multifactorial intervention
Number of subjects: 5000
Study 31638491 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratic support vector machine model for predicting ventilation maps
Number of subjects: 95
Study 31638491 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted ventilation defect percentage (VDP)
Number of subjects: 95
Study 31638491 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted VDP
Number of subjects: 95
Study 27753650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR (82.5 to 660 mg/d)
Number of subjects: 801
Study 27753650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study 25541333 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every other week for 24 weeks, then open-label adalimumab for up to 5 years
Number of subjects: 311
Study 25541333 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 311
Study 24285582 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin
Number of subjects: 12
Study 22555264 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention delivered in 3 modules through nurse-led face-to-face counseling, computer-based education, and written teaching materials
Number of subjects: 155
Study 22555264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study 19532100 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide and ACE-inhibitor (if needed)
Number of subjects: 0
Study 19532100 — intervention group
Group type: COMPARATOR
Intervention: ACE-inhibitor and angiotensin receptor blocker therapy
Number of subjects: 0
Study 19532100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics, ACE-inhibitors, or angiotensin receptor blockers (if ACE-inhibitor intolerant)
Number of subjects: 0
Study 17431603 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tadalafil
Number of subjects: 227
Study 17431603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil
Number of subjects: 227
Study 17431603 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 227